**Name of journal:** **World Journal of Gastroenterology**

**ESPS Manuscript NO: 13660**

**Columns: ORIGINAL ARTICLE**

***Prospective Study***

**Impact of direct acting antiviral-based triple therapy on the serum alpha-fetoprotein level** **of chronic hepatitis C patients**

Takayama K *et al*. Alpha-fetoprotein and direct acting antiviral therapy

Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Motohiro Shimizu, Masayuki Murata, Jun Hayashi

**Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Motohiro Shimizu, Masayuki Murata,** Department of General Internal Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan

**Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki,** Department of Environmental Medicine and Infectious Disease, Kyushu University, Fukuoka 812-8582, Japan

**Jun Hayashi,** Kyushu General Internal Medicine Center, Hara-Doi Hospital, Fukuoka 813-8588, Japan

**Author contributions:** The conception and design of the study was carried out by Takayama K and Furusyo N; The acquisition of data was done by Takayama K, Furusyo N, Ogawa E, Ikezaki H, Shimizu M and Murata M; The data were analyzed and interpreted by Takayama K and Furusyo N; and Takayama K and Furusyo N, Ogawa E and Hayashi J contributed to the drafting of the paper and its revision and are responsible for the intellectual content.

**Ethics approval:** The study was reviewed and approved by the ethics committee of Kyushu University Hospital.

**Clinical trial registration:** The study was registered as a clinical trial on the University Hospital Medical Information Network (ID 000013784).

**Informed consent:** Written informed consent was obtained from each participant prior to the examination.

**Conflict-of-interest:** Norihiro Furusyo has received an investigator initiated study research grant from Janssen Pharmaceutical KK. He has also received research funding from Mitsubishi Tanabe Pharma Co., MSD KK, Chugai Co., Daiichi Sankyo Co., and Bristol-Myers KK. The remaining authors have no conflicts of interest.

**Data sharing:** Technical appendix, statistical code, and dataset are available from the corresponding author at (furusyo@gim.med.kyushu-u.ac.jp). No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Norihiro Furusyo, MD, PhD,** Department of General Internal Medicine, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. furusyo@gim.med.kyushu-u.ac.jp

**Telephone:** +81-92-6425909

**Fax:** +81-92-6425210

**Received:** August 28, 2014

**Peer-review started:** August 31, 2014

**First decision:** September 27, 2014

**Revised:** December 9, 2014

**Accepted:** January 21, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To investigate the impact of telaprevir-based triple therapy on the serum alpha-fetoprotein (AFP) levelof chronic hepatitis C patients.

**METHODS:** A total of 210 patients with chronic hepatitis C genotype 1 of high viral load (baseline serum hepatitis C virus RNA > 5.0 log10 IU/mL) were divided into two groups by type of treatment: Triple therapy with telaprevir, pegylated-interferon alpha (PEG-IFNα), and ribavirin (RBV) for 24 wk (*n =* 88) or dual therapy with PEG-IFNα and RBV for 48 wk (*n =* 122). The relation between virological response and the change of the serum AFP level from baseline to 24 wk after the end of treatment was examined.

**RESULTS:** No significant difference in mean baseline AFP level was found between the triple and dual therapy groups (8.8 ng/mL *vs* 7.8 ng/mL, *P =* 0.677). Triple therapy produced a significant decline of the AFP level of both sustained virological response (SVR) and non-SVR patients (7.8 at baseline to 3.5 ng/mL at 24 wk after the end of treatment, *P <* 0.001 and 14.3 to 9.5 ng/mL, *P =* 0.004, respectively). Dual therapy resulted in a significant decline for SVR patients (4.7 to 2.8 ng/mL, *P <* 0.001), but not for non-SVR patients (10.2 to 10.1 ng/mL, *P =* 0.953). Among patients with a high baseline AFP level (≥ 10 ng/mL), the decline of the AFP level was significantly higher in the triple therapy than in the dual therapy group (15.9 ng/mL *vs* 1.6 ng/mL, *P =* 0.037).

**CONCLUSION:** Regardless of virological response, telaprevir-based triple therapy reduced the serum AFP level.

**Key words:** Chronic hepatitis C; Hepatocellular carcinoma; Direct-acting antiviral agents; Telaprevir; Serum alpha-fetoprotein

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The serum concentration of alpha-fetoprotein (AFP) is often elevated in patients with hepatocellular carcinoma (HCC), and a high AFP level has been reported to be a risk factor for the development of HCC by chronic hepatitis C patients. A recently introduced direct-acting antiviral agent, telaprevir (TVR), has been included in triple therapy regimens that include a protease inhibitor with conventional pegylated-interferon alpha (PEG-IFNα) and ribavirin (RBV), which has significantly improved the sustained virological response rate, up to 80% for patients with hepatitis C virus genotype 1. Regardless of virological response, TVR-based triple therapy more effectively reduces the serum alpha-fetoprotein level than does dual therapy with PEG-IFNα and RBV.

Takayama K, Furusyo N, Ogawa E, Ikezaki H, Shimizu M, Murata M, Hayashi J. Impact of direct acting antiviral-based triple therapy on the serum alpha-fetoprotein level of chronic hepatitis C patients. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Chronic hepatitis C virus (HCV) infection affects approximately 170 million people worldwide and often causes liver cirrhosis and hepatocellular carcinoma (HCC), a leading cause of cancer-related death[1,2]. One of the goals of chronic hepatitis C treatment is to achieve sustained viral response (SVR), which leads to the suppression of liver cirrhosis and HCC.

The combination therapy of pegylated interferon alpha (PEG-IFNα) and ribavirin (RBV) done for the last decade has improved the SVR rate to around 50% for chronic hepatitis C patients infected with HCV genotype 1[3-5]. Interferon therapy is effective in reducing the development of HCC, not only for SVR patients but also for non-SVR patients[6]. Recently direct-acting antiviral agent (DAA), telaprevir (TVR) and boceprevir, HCV non-structural 3/4A (NS3/4A) protease inhibitors, have been introduced, and triple therapy regimens that include second-generation NS3/4A protease inhibitors with conventional PEG-IFNα and RBV have significantly improved the SVR rate, up to 80% for patients with HCV genotype 1[7-11].

We previously reported the results of a prospective, long-term follow-up study done to evaluate the effect of treatment outcome on the development of HCC by Japanese patients (*n =* 1013) with chronic hepatitis C who were treated with PEG-IFNα2b and RBV[6]. Patients who achieved SVR or relapsed had a significantly reduced risk of HCC development within five years after the end of treatment when compared with patients without virological response, with or without cirrhosis. However, there is no data on the efficacy of NS3/4A protease inhibitors for reducing the number of patients who develop HCC.

Serum concentration of alpha-fetoprotein (AFP) is often elevated in patients with HCC[12], and a high AFP level has been reported to be a risk factor for the development of HCC by chronic hepatitis C patients[13]. In addition, accumulating evidence indicates that interferon treatment has the effect of reducing the serum AFP level, and the post-interferon treatment AFP level is strongly associated with the development of HCC, regardless of whether or not SVR is achieved[14-17].

The aim of this prospective study was to investigate the impact of DAA-based triple therapy on the serum AFP level. We also compare the post-treatment serum AFP level of triple therapy patients and patients treated with PEG-IFNα and RBV dual therapy.

**MATERIALS AND METHODS**

***Patients***

Patients were enrolled at Kyushu University Hospital and four affiliated hospitals and one clinic in the northern Kyushu area of Japan (Mitsutake, Yokota, Kyushu Central, and Hara-Doi Hospitals, and the Kyushu General Internal Medicine Clinic). This multicenter cohort study consisted of 354 genotype 1 chronic hepatitis C patients, without human immunodeficiency virus or hepatitis B virus infection, who received TVR-based triple therapy or dual therapy with PEG-IFNα2b and RBV. Triple therapy was initiated between December 2011 and March 2013 and was completed by the end of September 2013. Dual therapy was initiated between June 2005 and August 2011 and was completed by the end of July 2012. In order to investigate the impact of treatment on the serum AFP level, measurement was done at baseline, at the end of treatment (EOT), and at 24 wk after EOT. ∆AFP, defined as the AFP level at 24 wk after EOT subtracted from baseline, and%∆AFP, defined as the percentage of AFP at 24 wk after EOT subtracted from baseline, were also calculated. Similarly, the alanine aminotransferase (ALT) level was measured, and ∆ALT and%∆ALT, during the same period, were calculated. The study design was approved by the ethics committee of Kyushu University Hospital, and it was carried out in accordance with the 1975 Declaration of Helsinki, as updated in 2008. The study was registered as a clinical trial on the University Hospital Medical Information Network (ID 000013784).

Patient inclusion criteria for the study required patients to be infected with HCV genotype 1and to have baseline serum HCV RNA > 5.0 log10 IU/mL. The exclusion criteria were as follows: (1) Presence of HCC at enrollment, or development of HCC within 24 wk after EOT; (2) shortening of treatment due to adverse effects, virological breakthrough, non-virological response (NVR), or dropout; (3) in the dual therapy group, extension of the standard 48-week therapy; (4) inadequate treatment dosage of 80% or less of the assigned total cumulative dosage of each drug; (5) positive for antibody to human immunodeficiency virus or positive for hepatitis B surface antigen; (6) clinical or biochemical evidence of hepatic decompensation; (7) excessive active alcohol consumption (≥ 60g alcohol/d) or drug abuse; (8) other forms of liver disease (*e.g.*, autoimmune hepatitis, alcoholic liver disease, hemochromatosis); or (9) treatment with antiviral or immunosuppressive agents prior to enrollment. Of the354 patients screened, 144 were excluded becausethey did not meet the above criteria, leaving the data of 210 available for analysis. Figure 1 shows a flowchart of the study design.

***Antiviral treatment***

All patients in the triple therapy group received 12 wk of TVR (Telavic; Mitsubishi Tanabe Pharma, Osaka, Japan), PEG-IFNα2b (PEG-Intron; MSD, Tokyo, Japan), and RBV (Rebetol; MSD) followed by an additional 12 wk of PEG-IFNα2b and RBV alone. All patients in the dual therapy group received 48 wk of PEG-IFNα2b and RBV. TVR 750 mg was administered orally three times a day, after meals at 8-h intervals. If marked anorexia, an elevation of serum creatinine, or severe anemia developed, the TVR dose could be reduced to 1500 mg/d (750 mg at a 12-h interval after each meal). PEG-IFNα2b was injected subcutaneously once weekly at a dose of 1.5 μg/kg. RBV was given orally at a daily dose of 600-1000 mg based on body weight (600 mg for patients weighing < 60 kg, 800 mg for those weighing 60-80 kg, and 1000 mg for those weighing > 80 kg). The above durations and dosages are those approved by the Japanese Ministry of Health, Labor, and Welfare.

***Efficacy of treatment***

Successful treatment was SVR, defined as undetectable serum HCV RNA at 24 wk after EOT. Relapse was defined as undetectable HCV RNA at EOT, but detectable at some time within the 24 wk of follow-up. Non-virological response (NVR) was defined as a less than 2 log10 IU/mL decrease in the HCV RNA level from baseline to week 12 of therapy (null response) or a more than 2 log10 IU/mL decrease in the HCV RNA level from baseline to week 12 of therapy, but still detectable at weeks 12 and 24 (partial response). Virological breakthrough was defined as the reappearance of HCV RNA at any time during the course of treatment. EOT response is defined as undetectable HCV RNA at EOT. We excluded 14 patients with NVR or virological breakthrough who stopped treatment and met the exclusion criteria. The virological response rates were analyzed by per-protocol analysis.

***Clinical and laboratory assessment***

Blood sampleswere taken at baseline, every week thereafter to week24 for the triple therapy group and to week 48 for the dual therapy group, and at 24 wk after EOT. Laboratory parameters included serum albumin, creatinine, total bilirubin,ALT, aspartate aminotransferase, γ-glutamyl transpeptidase,estimated glomerular filtration rate, white blood cell count,hemoglobin, platelet count, and serum HCV markers.

HCV genotyping was performed by sequence determination in the 5’-non-structural regionof the HCV genome. The serum HCV RNA level of each patient was determined by COBAS TaqMan HCV Test (RocheDiagnostics, Tokyo, Japan). The test has lower and upper limits of quantitation of 15 IU/mL and 6.9 × 106 IU/mL, respectively, (1.2 to 7.8 log IU/mL referred to log10 IU/mL).

Human genomic DNA was extracted from peripheral blood. Genotyping by the single nucleotide polymorphism (SNP) of the interleukin 28B (IL28B) (rs8099917) gene was done using the TaqMan Allelic Discrimination Demonstration Kit (7500 Real-Time PCR System; Applied Biosystems, Foster City, CA). Patients were genotyped as TT, TG, or GG at the polymorphic site. The IL28B SNPs data were available for 192 (91.4%) of the 210 participants.

***Assessment of liver fibrosis***

Liver biopsy was done atenrollment for 148 (70.5%) of the 210 participants by two or more experiencedhepatologists. The minimum length of the liver biopsy was 15mm and at least 10 complete portal tracts were necessary for inclusion. For each specimen, the stage of fibrosis (F0-4) andthe grade of activity (A0-3) were established according to the METAVIR score[18].

***Statistical analysis***

All data were analyzed using JMP® statistical software (SAS Institute, Cary, NC, United States). Continuous data are expressed as median [first-third quartiles] or mean ± se and compared using Student's t*-*test or Mann-Whitney *U* test. Categorical variables are reported as frequencies and percentages and compared using Chi-square test or Fisher's exact test. The serum AFP and ALT levels at each test point are expressed as mean ± se, and comparison between these levels at baseline and at 24 wk after EOT was done by paired t-test. ∆AFP, %∆AFP, ∆ALT, and%∆ALT are expressed using a mean value histogram and standard error bar, and comparison of each subgroup was done by Student's t*-*test or Mann-Whitney *U* test. A *P* value <0.05 was regarded as statistically significant in all analyses.

**RESULTS**

***Patient characteristics***

The patient characteristics are summarized in Table 1according to the treatment given. The 63 triple therapy patients with prior relapse, NVR, or unknown response had previously undergone a 48-wk course PEG-IFNα2b plus RBV combination treatment. The baseline HCV RNA level of the triple therapy group was significantly higher than that of the dual therapy group (*P =* 0.010). The baseline platelet count of the triple therapy group was significantly lower than that of the dual therapy group (*P =* 0.040). Thus, the triple therapy group had more “difficult-to-treat” patients than did the dual therapy group. There was no significant difference between the groups in the number of patients tested for liver histology, IL28B SNPs, or other laboratory data. No significant difference in the baseline AFP level was observed between the two groups (4.5 ng/mL *vs* 4.0 ng/mL, *P =* 0.677), and the percentage of patients with AFP < 5 ng/mL, 5-9.9 ng/mL or ≥ 10 ng/mL did not differ.

***Virological response***

To investigate the impact of treatment on the serum AFP level, we excluded from the analysis patients with shortened or extended treatment or inadequate treatment dose (Figure 1). The SVR rate was significantly higher in the triple therapy group (75 of 88, 85.2% *vs* 52 of 122, 42.6%, *P <* 0.001). The relapse rate was lower in the triple therapy group (11 of 88, 12.5% *vs* 28 of 122, 23.0%, *P* = 0.050). Table 2shows the virological response of each treatment group according to previous treatment response, IL28B SNPs, stage of fibrosis, baseline HCV RNA level, baseline platelet count, and baseline serum AFP level. Significant differences in the SVR rates were observed for all of the subgroups except for advanced fibrosis (F3-4), probably due to the small number analyzed.

***Serum AFP level reduction***

Table 3 shows the serum AFP levels at baseline, EOT, and 24 wk after EOT according to the treatment outcome, baseline AFP level, previous treatment response, IL28B SNPs, and stage of fibrosis. The AFP level of all subgroups of the triple therapy group decreased significantly from baseline to 24 wk after EOT. In the dual therapy group, a significant decline in the AFP level was seen for patients with SVR, low baseline serum AFP (< 10 ng/mL), IL28B SNPs TT, and mild fibrosis (F0-2).

Figure 2 shows ∆AFP and%∆AFP by treatment and virological outcome. ∆AFP and%∆AFP did not significantly differ between the triple and dual therapy SVR patients (4.3 ± 1.4 ng/mL *vs* 1.9 ± 0.5 ng/mL, *P =* 0.248 and 27.4% ± 3.5% *vs* 24.4% ± 4.1%, *P =* 0.543, respectively). However, among the non-SVR patients, ∆AFP and%∆AFP were significantly higher in the triple than in the dual therapy group (4.7 ± 1.5 ng/mL *vs* 0.1 ± 1.4 ng/mL, *P =* 0.031 and 26.4% ± 6.1% *vs* 5.9% ± 4.3%, *P =* 0.033, respectively).

Figure 3 shows ∆AFP and%∆AFP by baseline AFP level (≥ 10 and < 10 ng/mL). ∆AFP did not significantly differ between the two groups for patients with a low baseline AFP level (< 10 ng/mL) (1.0 ± 0.2 ng/mL *vs* 0.7 ± 0.2 ng/mL, *P =* 0.059). However, among patients with a high baseline AFP level (≥ 10 ng/mL), ∆AFP was significantly higher in the triple than in the dual therapy group (15.9 ± 4.6 ng/mL *vs* 1.6 ± 4.0 ng/mL, *P =* 0.037).%∆AFP was significantly higher in the triple than in the dual therapy group (among patients with a low baseline AFP level, 20.2% ± 3.2% *vs* 11.7% ± 2.9%, *P =* 0.044; among patients with a high baseline AFP level, 51.2% ± 5.5% *vs* 20.2% ± 3.2%, *P =* 0.036).

***ALT level reduction after treatment***

Table 4 shows the ALT levels at baseline, EOT, and 24 wk after EOT according to treatment outcome, baseline ALT level, previous treatment response, IL28B SNPs, and stage of fibrosis. In the triple therapy group, all of the subgroups except non-SVR achieved a significant decline of the ALT level. However, in the dual therapy group, patients with SVR, high baseline ALT level (≥ 40 U/L), IL28B SNPs TT, and mild fibrosis (F0-2) achieved a significant decline of the ALT level.

Figure 4 shows ∆ALT and%∆ALT by baseline ALT level (≥ 40 and < 40 U/L). They did not significantly differ between the two groups for patients with a high baseline ALT level (≥ 40 U/L) (52.9 ± 5.7 U/L *vs* 44.3 ± 6.5 U/L, *P =* 0.168 and 60.5% ± 4.1% *vs* 44.9% ± 5.2%, *P =* 0.137, respectively). However, among patients with a low baseline ALT level (< 40 U/L), both were significantly greater in the triple than in the dual therapy group (10.0 ± 1.4 U/L *vs* 1.5 ± 3.1 U/L, *P =* 0.010 and 38.5% ± 4.7% *vs* 0.8% ± 10.9%, *P =* 0.007, respectively).

∆ALT and%∆ALT did not significantly differ between the non-SVR patients of the two groups (19.2 ± 12.4 U/L *vs* 6.5 ± 4.7 U/L, *P =* 0.427 and 11.5% ± 11.2% *vs* -2.7% ± 7.3%, *P =* 0.405, respectively). However, among the SVR patients, ∆ALT and%∆ALT were significantly higher in the dual than in the triple therapy group (59.0 ± 7.1 U/L *vs* 36.5 ± 4.1 U/L, *P =* 0.003 and 71.7% ± 2.6% *vs* 57.5% ± 2.7%, *P <* 0.001, respectively). This may be related to the significant difference in the baseline ALT level between the SVR patients (triple therapy group 54.3 ± 4.3 U/L and dual therapy group 74.0 ± 7.3 U/L, *P =* 0.018).

**DISCUSSION**

One of the most commonly used surveillance tests for HCC is measurement of serum AFP level. To our knowledge, this is the first study to compare the treatment effect of therapy for HCV that includes a DAA and conventional PEG-IFNα plus RBV dual therapy on serum AFP. We documented that, regardless of virological response and ALT change, the serum AFP level of all categories in the TVR-based triple therapy group decreased significantly from baseline to 24 wk after EOT, but no significant decline was found among non-SVR patients of the dual therapy group with a high baseline serum AFP (≥ 10 ng/mL), who were IL28B SNPs TG/GG (non-TT), or stage of fibrosis F3-4.

For chronic hepatitis C patients whose serum AFP level before interferon therapy is ≥ 10 ng/mL, a reduction of the average AFP integration value to < 10 ng/mL by treatment has been strongly associated with a reduced rate of the development of HCC[14]. Moreover, a significantly higher cumulative development of HCC was found for patients with an increased serum AFP level (≥ 10 ng/mL) at EOT, and virological response was not a significant predictive factor[17]. Our study showed a significantly higher decline of the serum AFP level in the TVR-based triple therapy than in the dual therapy group among non-SVR patients or those who had a higher baseline AFP level (≥ 10 ng/mL). This finding suggests the possibility that TVR-based triple therapy has a greater benefit than PEG-IFNα and RBV therapy for the suppression of HCC, through a greater reduction of the serum AFP level.

For chronic hepatitis C patients, the HCV-coding core protein is known to upregulate several molecules to activate the cell cycle and proliferation at the transcription level in hepatocytes and it may also up-regulate AFP production at the transcription level[19], therefore, mild elevation of the serum AFP level is sometimes seen in patients with chronic active hepatitis C but without HCC[15,20]. The percentage of an elevated AFP level (≥ 10 ng/mL) for chronic hepatitis C patients ranges from 11.6% to 43%[20-22]. Interferon induces p53 gene transcription to down-regulate the cell cycle at the transcriptional level or to evoke an apoptotic response of cancerous cells[23,24], with these antitumor effects probably playing an important role in reducing the AFP level after interferon therapy[19]. RBV enhances the curative effect of interferon in the treatment of chronic hepatitis C[25,26], however, there is no evidence to date for its efficacy in reducing the serum AFP level. RBV monotherapy has no effect on the serum HCV RVA level, even though a transient decline in the ALT level was observed during the treatment period[27,28], thus a reduction of the serum AFP level by RBV seems unlikely. In this study, TVR-based triple therapy resulted in a more significant reduction of the serum AFP level than did PEG-IFNα plus RBV dual therapy, in spite of the shorter duration of PEG-IFNα than is done in dual therapy. We presume the reason is that TVR directly works as an HCV NS3/4A protease inhibitor for anti-replication of HCV. NS3/4A is thought to contribute to the development of HCV-associated promotion of hepatocyte growth, which may develop into hepato-carcinogenesis, as do HCV core, NS5A, and NS5B proteins[29,30]. Therefore, not only TVR but also other promising DAAs such as HCV NS5A or NS5B inhibitor should have potentially similar effects that would result in a reduction of the serum AFP level and have the potential to reduce the risk of developing HCC.

The persistence of ALT elevation is a convenient marker for identifying an increased risk for HCC[31], providing that chronic inflammation in the liver is related to HCC development. In fact, the cumulative development of HCC was significantly higher for SVR patients whose post-interferon treatment AFP and ALT levels were high (≥ 10 ng/mL and ≥ 40 U/L, respectively), as well as for non-SVR patients (≥ 6.0 ng/mL or ≥ 40 U/L, respectively)[15]. Our study showed that TVR-based triple therapy did not significantly decrease the ALT level of non-SVR patients, and no significant difference in the decline of the ALT level after treatment was observed between patients of the triple and dual therapy groups with high baseline ALT (≥ 40 U/L). However, regardless of virological response and ALT decline, TVR-based triple therapy reduced the serum AFP level in our study. These findings show that the significant reduction of the serum AFP level by DAA-based therapy for chronic hepatitis C patients may not be related to an anti- inflammation affect.

IL28B (rs8099917) non-TT genotype is widely known to be related to reduced rates of successful treatment in both telaprevir-based triple therapy and dual therapy of PEG-IFNα and RBV[5,8,32]. Moreover, high levels of baseline AFP are a surrogate marker for predicting treatment failure in telaprevir-based triple therapy for patients with the IL28B non-TT genotype[33]{Shimada, 2014 #79}. To apply this to our study, the SVR rate of IL28B non-TT genotype patients undergoing telaprevir-based triple therapy was significantly lower in the high baseline AFP level group (*i.e.*, ≥ 10 ng/mL) than in the low baseline AFP level group (46.2% *vs* 80.8%, *P =* 0.027). These findings suggest that a high baseline AFP level may be a useful surrogate marker for predicting treatment failure in other DAA-based triple therapy regimens for patients with IL28B non-TT genotype.

Recent developments in molecular biology have led to the identification of new tumor markers for HCC (heat shock protein 70, AFP-L3, fucosylated GP73, α-L-fucosidase, squamous cell carcinoma antigen, glypican-3, transforming growth factor-β1, and endothelial growth factor), including proteantigens, cytokines, enzymes and isoenzymes, as well as related genes that can be used in the treatment and prognosis of liver cancer[34]. Additional studies are likely to show these novel markers to be improved by antiviral treatment.

Limitations of this study are that it was not randomized and that our participants were all Japanese with HCV genotype 1. In addition, the age of our participants is relatively old (51.4%, 108 of 210 participants are older than 60 years), thus it will be necessary to determine if our results apply to younger patients. However, older aged chronic hepatitis C patients have a higher risk for the development of HCC[6,14,15]. We believe that our study provides valuable information on the efficacy of DAAs in reducing the serum AFP level.

In conclusion, TVR-based triple therapy more effectively reduces the serum AFP level, even of non-SVR patients, than does dual therapy with PEG-IFNα and RBV.

**Acknowledgments**

The authors thank Drs. Mosaburo Kainuma, Kazuhiro Toyoda, Haru Mukae, Takeshi Ihara, Takeo Hayashi, Yuji Harada, Sakiko Hayasaki, Norihito Satoh, Fujiko Mitsumoto, Satoshi Hiramine, Kazuya Ura, Yoshifumi Kato, and Masaru Yamasaki from our department for assistance with data collection. The authors also thank Mr. Yoshitaka Etoh for his excellent lab work on IL28B SNPs.

**COMMENTS**

***Background***

Serum concentration of alpha-fetoprotein (AFP) is often elevated in patients with hepatocellular carcinoma (HCC), and a high AFP level has been reported to be a risk factor for the development of HCC in chronic hepatitis C patients. Accumulating evidence indicates that interferon treatment has the effect of reducing the serum AFP level, and the post-interferon treatment AFP level is strongly associated with the suppression of HCC, regardless of whether or not sustained viral response (SVR) is achieved.

***Research frontiers***

Combining direct acting antiviral agents (DAAs) with pegylated-interferon alpha (PEG-IFNα) and ribavirin (RBV) has resulted in an improved SVR rate. However, there is no data on the efficacy of DAA on reducing the development of HCC. This cohort study was done to compare the impact on the serum AFP level of telaprevir-based triple therapy or conventional dual therapy with PEG-IFNα and RBV.

***Innovations and breakthroughs***

This is the first study to compare the treatment effect of therapy for HCV that includes a DAA and conventional PEG-IFNα plus RBV dual therapy on serum AFP.

***Applications***

By understanding the efficacy of DAA on the reduction of serum AFP level, this study provides evidence that therapy that includes a DAA has the potential to dramatically reduce the risk of developing HCC.

***Terminology***

The combination therapy of PEG-IFNα and RBV done for the last decade has improved the SVR rate to around 50% for chronic hepatitis C patients infected with HCV genotype 1. Interferon therapy is effective in reducing the number of patients who develop HCC, not only for SVR patients but also for non-SVR patients. DAAs, HCV non-structural 3/4A (NS3/4A) protease inhibitors, have recently been introduced, and triple therapy regimens that include a protease inhibitor with conventional PEG-IFNα and RBV have significantly improved the SVR rate, up to 80% for patients with HCV genotype 1.

***Peer-review***

This manuscript is an interesting study that aims to investigate the effect of TVR-based triple therapy on the serum AFP level.

**REFERENCES**

1 **Lavanchy D**. Evolving epidemiology of hepatitis C virus. *Clin Microbiol Infect* 2011; **17**: 107-115 [PMID: 21091831 DOI: 10.1111/j.1469-0691.2010.03432.x]

2 **Thomas DL**. Global control of hepatitis C: where challenge meets opportunity. *Nat Med* 2013; **19**: 850-858 [PMID: 23836235 DOI: 10.1038/nm.3184]

3 **Furusyo N**, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Masumoto A, Maruyama T, Nakamuta M, Enjoji M, Azuma K, Shimono J, Sakai H, Shimoda S, Hayashi J. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group. *J Gastroenterol Hepatol* 2008; **23**: 1094-1104 [PMID: 18248381 DOI: 10.1111/j.1440-1746.2008.05319.x]

4 **Manns MP**, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; **358**: 958-965 [PMID: 11583749]

5 **Ogawa E**, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. *J Hepatol* 2012; **57**: 534-540 [PMID: 22613000 DOI: 10.1016/j.jhep.2012.04.027]

6 **Ogawa E**, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. *J Hepatol* 2013; **58**: 495-501 [PMID: 23099187 DOI: 10.1016/j.jhep.2012.10.017]

7 **Manns MP**, Gane E, Rodriguez-Torres M, Stoehr A, Yeh CT, Marcellin P, Wiedmann RT, Hwang PM, Caro L, Barnard RJ, Lee AW. Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study. *Hepatology* 2012; **56**: 884-893 [PMID: 22473713 DOI: 10.1002/hep.25743]

8 **Furusyo N**, Ogawa E, Murata M, Toyoda K, Ohnishi H, Eiraku K, Shimizu M, Harada Y, Mitsumoto F, Takayama K, Kainuma M, Okada K, Hayashi J. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. *J Antimicrob Chemother* 2014; **69**: 483-490 [PMID: 24092661 DOI: 10.1093/jac/dkt371]

9 **Furusyo N**, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. *J Hepatol* 2013; **59**: 205-212 [PMID: 23542346 DOI: 10.1016/j.jhep.2013.03.020]

10 **Fried MW**, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. *Hepatology* 2013; **58**: 1918-1929 [PMID: 23907700 DOI: 10.1002/hep.26641]

11 **Poordad F**, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med* 2011; **364**: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]

12 **Peterson ML**, Ma C, Spear BT. Zhx2 and Zbtb20: novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancer. *Semin Cancer Biol* 2011; **21**: 21-27 [PMID: 21216289 DOI: 10.1016/j.semcancer.2011.01.001]

13 **Tateyama M**, Yatsuhashi H, Taura N, Motoyoshi Y, Nagaoka S, Yanagi K, Abiru S, Yano K, Komori A, Migita K, Nakamura M, Nagahama H, Sasaki Y, Miyakawa Y, Ishibashi H. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. *J Gastroenterol* 2011; **46**: 92-100 [PMID: 20711614 DOI: 10.1007/s00535-010-0293-6]

14 **Osaki Y**, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, Nishikawa H, Saito S, Henmi S, Sakamoto A, Eso Y, Chiba T. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. *J Gastroenterol* 2012; **47**: 444-451 [PMID: 22105231 DOI: 10.1007/s00535-011-0505-8]

15 **Asahina Y**, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. *Hepatology* 2013; **58**: 1253-1262 [PMID: 23564522 DOI: 10.1002/hep.26442]

16 **Oze T**, Hiramatsu N, Yakushijin T, Miyazaki M, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, Takehara T. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. *Clin Gastroenterol Hepatol* 2014; **12**: 1186-1195 [PMID: 24321207 DOI: 10.1016/j.cgh.2013.11.033]

17 **Tamura Y**, Yamagiwa S, Aoki Y, Kurita S, Suda T, Ohkoshi S, Nomoto M, Aoyagi Y. Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. *Dig Dis Sci* 2009; **54**: 2530-2537 [PMID: 19093203 DOI: 10.1007/s10620-008-0642-y]

18 **Group TFMCS**. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. *Hepatology* 1994; **20**: 15-20 [PMID: 8020885]

19 **Murashima S**, Tanaka M, Haramaki M, Yutani S, Nakashima Y, Harada K, Ide T, Kumashiro R, Sata M. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. *Dig Dis Sci* 2006; **51**: 808-812 [PMID: 16615008 DOI: 10.1007/s10620-006-3211-2]

20 **Hu KQ**, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. *Am J Gastroenterol* 2004; **99**: 860-865 [PMID: 15128351 DOI: 10.1111/j.1572-0241.2004.04152.x]

21 **Fattovich G**, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. *Gastroenterology* 1997; **112**: 463-472 [PMID: 9024300]

22 **Kobeisy MA**, Morsy KH, Galal M, Sayed SK, Ashmawy MM, Mohammad FM. Clinical significance of elevated alpha-foetoprotein (AFP) in patients with chronic hepatitis C without hepatocellular carcinoma in upper EGYPT. *Arab J Gastroenterol* 2012; **13**: 49-53 [PMID: 22980591 DOI: 10.1016/j.ajg.2012.06.004]

23 **Takaoka A**, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. *Nature* 2003; **424**: 516-523 [PMID: 12872134 DOI: 10.1038/nature01850]

24 **Vousden KH**, Lu X. Live or let die: the cell's response to p53. *Nat Rev Cancer* 2002; **2**: 594-604 [PMID: 12154352 DOI: 10.1038/nrc864]

25 **Zoulim F**, Haem J, Ahmed SS, Chossegros P, Habersetzer F, Chevallier M, Bailly F, Trépo C. Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. *J Viral Hepat* 1998; **5**: 193-198 [PMID: 9658373]

26 **Schalm SW**, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. *J Hepatol* 1997; **26**: 961-966 [PMID: 9186825]

27 **Lee JH**, von Wagner M, Roth WK, Teuber G, Sarrazin C, Zeuzem S. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. *J Hepatol* 1998; **29**: 29-35 [PMID: 9696489]

28 **Bodenheimer HC**, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. *Hepatology* 1997; **26**: 473-477 [PMID: 9252161 DOI: 10.1002/hep.510260231]

29 **Banerjee A**, Ray RB, Ray R. Oncogenic potential of hepatitis C virus proteins. *Viruses* 2010; **2**: 2108-2133 [PMID: 21994721 DOI: 10.3390/v2092108]

30 **El-Shamy A**, Shindo M, Shoji I, Deng L, Okuno T, Hotta H. Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma. *Hepatology* 2013; **58**: 555-563 [PMID: 23281009 DOI: 10.1002/hep.26205]

31 **Hayashi J**, Furusyo N, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S. A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. *J Infect Dis* 2000; **181**: 1523-1527 [PMID: 10823749 DOI: 10.1086/315431]

32 **Tanaka Y**, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 2009; **41**: 1105-1109 [PMID: 19749757 DOI: 10.1038/ng.449]

33 **Shimada N**, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y, Aizawa Y. α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype. *J Med Virol* 2014; **86**: 461-472 [PMID: 24166425 DOI: 10.1002/jmv.23824]

34 **Zhao YJ**, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma. *Mol Clin Oncol* 2013; **1**: 593-598 [PMID: 24649215 DOI: 10.3892/mco.2013.119]

**P-Reviewer:** Bolhassani A, Lopez-Rodriguez R, tong HL **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

Figure1

**Figure 1 Flowchart of the study design.** HIV: Human immunodeficiency virus; HBV: Hepatitis B virus; NVR: Non-virological response; HCC: Hepatocellular carcinoma; Triple therapy: Telaprevir-based therapy combined with pegylated interferon alpha (PEG-IFNα) and ribavirin (RBV); Dual therapy: PEG-IFNαplus RBV therapy.



**Figure 2 ∆ alpha-fetoprotein and %∆ alpha-fetoprotein by treatment and virological outcome.** ∆AFP is defined as the AFP level at 24 wk after end of treatment subtracted from baseline. %∆AFP is defined as the percentage of AFP at 24 wk after end of treatment subtracted from baseline. The vertical bars represent the standard errors of the mean. Triple therapy: Telaprevir-based therapy combined with pegylated interferon alpha (PEG-IFNα) and ribavirin (RBV); Dual therapy: PEG-IFNα plus RBV therapy; SVR: sustained virological response.



**Figure 3 ∆ alpha -fetoprotein and%∆ alpha -fetoprotein by baseline alpha -fetoprotein level (≥ 10 and < 10 ng/mL).** ∆AFP is defined as the alpha -fetoprotein (AFP) level at 24 wk after end of treatment subtracted from baseline.%∆AFP is defined as the percentage of AFP at 24 wk after end of treatment subtracted from baseline. The vertical bars represent the standard errors of the mean. Triple therapy: Telaprevir-based therapy combined with pegylated interferon alpha (PEG-IFNα) and ribavirin (RBV); Dual therapy: PEG-IFNα plus RBV therapy.



**Figure 4 ∆ alanine aminotransferase and%∆ alanine aminotransferase by baseline alanine aminotransferase level (≥ 40 and < 40 U/L).** ∆ alanine aminotransferase (ALT) is defined as the ALT level at 24 wk after end of treatment subtracted from baseline.%∆ALT is defined as the percentage of ALT at 24 wk after end of treatment subtracted from baseline. The vertical bars represent the standard errors of the mean. Triple therapy: Telaprevir-based therapy combined with pegylated interferon alpha (PEG-IFNα) and ribavirin (RBV); Dual therapy: PEG-IFNα plus RBV therapy.

**Table 1 Baseline demographic characteristics, classified by treatment *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Baseline characteristics** | **Triple therapy (*n =* 88)** | **Dual therapy (*n =* 122)** | ***P* value1** |
| Age (yr) | 63 (53-68) | 60 (52-65) | 0.101 |
| Male | 37 (42.1) | 52 (42.6) | 0.933 |
| Body weight (kg) | 56 (49-67) | 58 (50-66) | 0.782 |
| Body mass index (kg/m2) | 22.7 (20.7-25.1) | 22.8 (20.6-24.9) | 0.859 |
| Serum AFP level (ng/mL) | 4.5 (2.8-9.0) | 4.0 (2.8-8.9) | 0.677 |
| Serum AFP level < 5 ng/mL | 50 (56.8) | 70 (57.4) | 0.967 |
| Serum AFP level 5-9.9 ng/mL | 18 (20.5) | 26 (21.3) |
| Serum AFP level ≥ 10 ng/mL | 20 (20.7) | 26 (21.3) |
| HCV RNA level (log10 IU/mL) | 6.5 (6.1-6.9) | 6.3 (5.8-6.6) | 0.010 |
| HCV genotype 1a | 1 (1.1) | 3 (2.5) | 0.476 |
| HCV genotype 1b | 87 (98.9) | 119 (97.5) |
| Serum albumin (g/L) | 41 (38-43) | 41 (39-43) | 0.376 |
| Alanine aminotransferase (U/L) | 46 (25-73) | 51 (33-81) | 0.176 |
| Alanine aminotransferase ≥ 40 IU/L | 49 (55.7) | 78 (63.9) | 0.228 |
| γ-glutamyl-transpeptidase (U/L) | 39 (23-76) | 37 (21-63) | 0.199 |
| Estimated glomerular filtration rate (mL/min per 1.73 m2) | 80 (68-94) | 81 (71-94) | 0.464 |
| Total cholesterol (mg/dL) | 175 (153-192) | 164 (146-192) | 0.216 |
| Triglycerides (mg/dL) | 94 (68-124) | 79 (57-121) | 0.070 |
| Aspartate aminotransferase to platelet ratio index | 0.86 (0.51-1.85) | 0.76 (0.50-1.40) | 0.306 |
| White blood cell count (× 106/L) | 4780 (4038-5890) | 4600 (3890-5645) | 0.447 |
| Hemoglobin level (g/L) | 137 (129-144) | 135 (126-145) | 0.319 |
| Platelet count (×109/L) | 156 (122-195) | 178 (136-209) | 0.040 |
| Diabetes | 10 (11.3) | 7 (5.7) | 0.144 |
| Stage of fibrosis |  |  |  |
| F0-2 | 52 (81.2) | 76 (90.5) | 0.105 |
| F3-4 | 12 (18.8) | 8 (9.5) |
| Not determined | 24 | 38 |  |
| Previous treatment response |  |  |  |
| Naïve | 25 (28.4) |  |  |
| Prior relapse | 34 (38.6) |  |
| Prior NVR | 27 (30.7) |  |
| Prior unknown response | 2 (2.3) |  |
| IL28B SNP (rs8099917) |  |  |  |
| TT | 49 (55.7) | 73 (70.2) | 0.113 |
| TG/GG | 39 (44.3) | 31 (29.8) |
| Not determined, n | 0 | 18 |  |

1*P* value draws a comparison between the triple and dual therapy groups. AFP: α-fetoprotein; HCV: Hepatitis C virus; NVR: Non-virological response; IL28B: Interleukin 28B; SNP: Single-nucleotide polymorphism; Triple therapy: Telaprevir-based therapy combined with pegylated-interferon alpha (PEG-IFNα) and ribavirin (RBV); Dual therapy: PEG-IFNα plus RBV therapy.

**Table 2** **Sustained virological response rates of each treatment group according to previous treatment response, interleukin 28B single nucleotide polymorphisms, stage of fibrosis, baseline hepatitis C virus RNA level, baseline platelet count, and baseline serum α-fetoprotein level *n* (%)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Triple therapy** | | **Dual therapy** | | ***P* value1** |
|  | *n* | SVR | *n* | SVR |  |
| All patients | 88 | 75 (85.2) | 122 | 52 (42.6) | < 0.001 |
| Previous treatment response |  |  |  |  |  |
| Naïve/prior relapse | 59 | 56 (94.9) |  |  |  |
| Prior NVR | 27 | 17 (63.0) |  |  |  |
| Prior unknown response | 2 | 2 (100) |  |  |  |
| IL28B SNP (rs8099917) |  |  |  |  |  |
| TT | 49 | 48 (98.0) | 73 | 45 (61.6) | < 0.001 |
| TG/GG | 39 | 27 (69.2) | 31 | 1 (3.2) | < 0.001 |
| Not determined, n | 0 | - | 18 | 6 (33.3) | - |
| Stage of fibrosis |  |  |  |  |  |
| F0-2 | 52 | 48 (92.3) | 76 | 43 (56.6) | < 0.001 |
| F3-4 | 12 | 9 (75.0) | 8 | 4 (50.0) | 0.279 |
| Not determined, n | 24 | 18 (75.0) | 38 | 5 (13.2) |  |
| Baseline HCV RNA level |  |  |  |  |  |
| ≥ 6 log10 IU/mL | 69 | 58 (84.1) | 86 | 39 (45.3) | < 0.001 |
| < 6 log10 IU/mL | 19 | 17 (89.5) | 36 | 23 (63.8) | 0.032 |
| Baseline platelet count |  |  |  |  |  |
| ≥ 100 × 109/L | 80 | 71 (88.8) | 117 | 62 (53.0) | < 0.001 |
| < 100 × 109/L | 8 | 4 (50.0) | 5 | 0 - | 0.043 |
| Baseline serum AFP level |  |  |  |  |  |
| < 10 ng/mL | 68 | 63 (92.6) | 96 | 49 (51.0) | < 0.001 |
| ≥ 10 ng/mL | 20 | 12 (60.0) | 26 | 3 (11.5) | < 0.001 |

1*P* value draws a comparison between the triple and dual therapy groups. NVR: Non-virological response; IL28B: Interleukin 28B; SNP: Single-nucleotide polymorphism; HCV: Hepatitis C virus; AFP: Alpha-fetoprotein; Triple therapy: Telaprevir-based therapy combined with pegylated interferon alpha (PEG-IFNα) and ribavirin (RBV); Dual therapy: PEG-IFNα plus RBV therapy. Treatment response was analyzed by per-protocol analysis.

**Table 3 Serum alpha-fetoprotein level change at each testing point according to treatment outcome, baseline alpha-fetoprotein level, previous treatment response, interleukin 28B single nucleotide polymorphisms, and stage of fibrosis, classified by treatment**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Triple therapy** | | | | | **Dual therapy** | | | | |
|  | Serum AFP level (ng/mL) | | | | | Serum AFP level (ng/mL) | | | | |
| Group | *n* | At baseline | At end of treatment | At 24 wk after the end of treatment | *P* value1 | *n* | At baseline | At end of treatment | At 24 wk after the end of treatment | *P* value1 |
| All patients | 88 | 8.8 ± 1.4 | 5.1 ± 0.4 | 4.4 ± 0.4 | < 0.001 | 122 | 7.8 ± 0.9 | 6.2 ± 1.3 | 7.0 ± 1.5 | 0.316 |
| Treatment outcome |  |  |  |  |  |  |  |  |  |  |
| SVR | 75 | 7.8 ± 1.5 | 4.5 ± 0.4 | 3.5 ± 0.2 | 0.004 | 52 | 4.7 ± 0.6 | 3.1 ± 0.2 | 2.8 ± 0.2 | < 0.001 |
| Non-SVR | 13 | 14.3 ± 2.3 | 8.3 ± 1.1 | 9.5 ± 1.2 | 0.007 | 70 | 10.2 ± 1.5 | 8.7 ± 2.2 | 10.1 ± 2.5 | 0.953 |
| Baseline AFP level |  |  |  |  |  |  |  |  |  |  |
| ≥10 ng/mL | 20 | 24.8 ± 4.4 | 10.5 ± 1.0 | 8.9 ± 0.8 | 0.003 | 26 | 21.8 ± 3.0 | 17.1 ± 5.3 | 20.2 ± 6.4 | 0.701 |
| <10 ng/mL | 68 | 4.1 ± 0.2 | 3.4 ± 0.2 | 3.1 ± 0.2 | < 0.001 | 96 | 4.1 ± 0.2 | 3.2 ± 0.2 | 3.4 ± 0.2 | < 0.001 |
| Previous treatment response |  |  |  |  |  |  |  |  |  |  |
| Naïve/Prior relapse | 59 | 8.8 ± 1.9 | 4.8 ± 0.5 | 3.8 ± 0.3 | 0.007 |  |  |  |  |  |
| Prior NVR | 27 | 9.1 ± 1.5 | 5.5 ± 0.8 | 5.8 ± 0.9 | < 0.001 |  |  |  |  |  |
| IL28B SNP  (rs8099917) |  |  |  |  |  |  |  |  |  |  |
| TT | 49 | 6.2 ± 1.0 | 3.9 ± 0.4 | 3.6 ± 0.3 | < 0.001 | 73 | 6.0 ± 0.7 | 3.7 ± 0.3 | 3.9 ± 0.3 | < 0.001 |
| TG/GG | 39 | 12.0 ± 2.8 | 6.5 ± 0.8 | 5.5 ± 0.6 | < 0.001 | 31 | 10.2 ± 1.6 | 8.8 ± 2.9 | 9.3 ± 2.2 | 0.520 |
| Stage of fibrosis |  |  |  |  |  |  |  |  |  |  |
| F0-2 | 52 | 6.5 ± 1.4 | 4.2 ± 0.5 | 3.3 ± 0.3 | 0.014 | 76 | 6.0 ± 0.7 | 3.7 ± 0.3 | 4.3 ± 0.5 | < 0.001 |
| F3-4 | 12 | 12.2 ± 3.0 | 6.5 ± 0.8 | 6.8 ± 1.1 | 0.023 | 8 | 13.6 ± 3.2 | 9.2 ± 3.2 | 9.9 ± 3.8 | 0.284 |

1*P* value draws a comparison between the alpha-fetoprotein (AFP) level at baseline and at 24 wk after the end of treatment. SVR: Sustained virological response; NVR: Non-virological response; IL28B: Interleukin 28B; SNP: Single-nucleotide polymorphism; Triple therapy: Telaprevir-based therapy combined with pegylated interferon alpha (PEG-IFNα) and ribavirin (RBV); Dual therapy: PEG-IFNα plus RBV therapy. Treatment response was analyzed by per-protocol analysis. Data are expressed as mean ± SE.

**Table 4** **Alanine aminotransferase level change at each testing point according to treatment outcome, baseline alanine aminotransferase level, previous treatment response, interleukin 28B single nucleotide polymorphisms, and stage of fibrosis, classified by treatment**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Triple therapy** | | | | | **Dual therapy** | | | | |
|  | ALT level (U/L) | | | | | ALT level (U/L) | | | | |
| Group | n | At baseline | At end of treatment | At 24 wk after the end of treatment | *P* value1 | n | At baseline | At end of treatment | At 24 wk after the end of treatment | *P* value1 |
| All patients | 88 | 56.6 ± 4.1 | 25.9 ± 2.4 | 22.7 ± 1.8 | < 0.001 | 122 | 64.1 ± 4.7 | 29.4 ± 4.0 | 35.3 ± 3.0 | < 0.001 |
| Treatment outcome |  |  |  |  |  |  |  |  |  |  |
| SVR | 75 | 54.3 ± 4.3 | 25.4 ± 2.7 | 17.8 ± 1.1 | < 0.001 | 52 | 74.0 ± 7.3 | 18.8 ± 1.6 | 14.9 ± 0.8 | < 0.001 |
| Non-SVR | 13 | 69.8 ± 12.2 | 28.8 ± 3.8 | 50.6 ± 6.0 | 0.147 | 70 | 56.8 ± 4.9 | 37.4 ± 6.7 | 50.4 ± 4.3 | 0.169 |
| Baseline ALT level |  |  |  |  |  |  |  |  |  |  |
| ≥40 U/L | 49 | 81.4 ± 5.1 | 32.9 ± 3.5 | 28.5 ± 2.8 | < 0.001 | 78 | 84.3 ± 5.4 | 36.6 ± 5.9 | 40.0 ± 4.2 | < 0.001 |
| <40 U/L | 39 | 25.4 ± 1.2 | 17.1 ± 2.6 | 15.4 ± 1.3 | < 0.001 | 44 | 28.3 ± 1.1 | 16.0 ± 1.7 | 26.8 ± 3.0 | 0.637 |
| Previous treatment response |  |  |  |  |  |  |  |  |  |  |
| Naïve/Prior relapse | 59 | 56.5 ± 5.2 | 25.5 ± 2.7 | 19.4 ± 1.5 | < 0.001 |  |  |  |  |  |
| Prior NVR | 27 | 56.7 ± 7.5 | 21.0 ± 2.5 | 28.6 ± 4.5 | < 0.001 |  |  |  |  |  |
| IL28B SNP  (rs8099917) |  |  |  |  |  |  |  |  |  |  |
| TT | 49 | 56.9 ± 5.4 | 26.6 ± 3.8 | 17.4 ± 1.3 | < 0.001 | 73 | 63.6 ± 5.4 | 18.9 ± 1.4 | 25.9 ± 2.4 | < 0.001 |
| TG/GG | 39 | 56.2 ± 6.5 | 24.9 ± 2.6 | 29.2 ± 3.5 | < 0.001 | 31 | 65.9 ± 9.4 | 38.8 ± 6.2 | 50.9 ± 5.2 | 0.073 |
| Stage of fibrosis |  |  |  |  |  |  |  |  |  |  |
| F0-2 | 52 | 51.6 ± 5.2 | 23.1 ± 3.2 | 17.6 ± 1.5 | < 0.001 | 76 | 63.4 ± 5.4 | 21.1 ± 1.7 | 25.4 ± 2.4 | < 0.001 |
| F3-4 | 12 | 68.8 ± 11.6 | 32.3 ± 5.6 | 27.5 ± 5.4 | 0.008 | 8 | 93.0 ± 25.8 | 34.8 ± 7.6 | 46.5 ± 11.8 | 0.172 |

1*P* value draws a comparison between the alanine aminotransferase (ALT) level at baseline and at 24 wk after the end of treatment. SVR: Sustained virological response; NVR: Non-virological response; IL28B: Interleukin 28B; SNP: Single-nucleotide polymorphism; Triple therapy: Telaprevir-based therapy combined with pegylated interferon alpha (PEG-IFNα) and ribavirin (RBV); Dual therapy: PEG-IFNα plus RBV therapy. Treatment response was analyzed by per-protocol analysis. Data are expressed as mean ± se.